文献速递复苏、休克与脓毒症心脑血管急症

血管加压素联合甲泼尼龙与安慰剂对院内心搏骤停患者长期结局的影响:一项随机临床试验

Effect of vasopressin and methylprednisolone vs. placebo on long-term outcomes in patients with in-hospital cardiac arrest a randomized clinical trial.
PubMed 文献 · Resuscitation · 2022-04-28
一句话结论VAM-IHCA试验长期随访显示,院内心搏骤停复苏时给予血管加压素40 mg甲泼尼龙与20 IU血管加压素未改善6个月及1年生存、神经功能结局或健康相关生活质量。

VAM-IHCA试验是在丹麦10家医院开展的多中心、随机、双盲、安慰剂对照试验,纳入院内心搏骤停且复苏中至少接受1剂肾上腺素的成人患者(年龄≥18岁),在首剂肾上腺素后尽早给予甲泼尼龙40 mg与血管加压素20 IU或安慰剂。本报告分析501例患者6个月与1年结局:1年时干预组15例(6.3%)存活、安慰剂组22例(8.3%)存活,风险比0.76(95%CI 0.41-1.41);1年神经功能良好结局(基于脑功能分类评分)干预组14例(5.9%)、安慰剂组20例(7.6%),风险比0.78(95%CI 0.41-1.49)。6个月与1年时两组神经功能良好结局及健康相关生活质量均无差异。作者结论为院内心搏骤停患者给予血管加压素与甲泼尼龙未改善长期结局。

要点

  • VAM-IHCA长期随访501例院内心搏骤停成人患者,1年存活干预组15例(6.3%)vs 安慰剂组22例(8.3%),风险比0.76(95%CI 0.41-1.41)。
  • 1年神经功能良好结局(脑功能分类评分)干预组14例(5.9%)vs 安慰剂组20例(7.6%),风险比0.78(95%CI 0.41-1.49)。
  • 6个月与1年时两组神经功能良好结局及健康相关生活质量均无差异。
  • 试验药物为甲泼尼龙40 mg与血管加压素20 IU,在首剂肾上腺素后尽早给药。

适用人群与场景

  • 丹麦10家医院、年龄≥18岁的院内心搏骤停成人患者,且复苏期间至少接受1剂肾上腺素。

处置流程与药物剂量

  • 试验方案:首剂肾上腺素后尽早给予甲泼尼龙40 mg与血管加压素20 IU(试验药物组合),对照为安慰剂。

研究设计与关键结果

  • VAM-IHCA为多中心、随机、双盲、安慰剂对照试验,在丹麦10家医院开展,纳入院内心搏骤停且至少接受1剂肾上腺素的成人患者,共501例纳入本分析。
  • 1年存活:干预组15例(6.3%)vs 安慰剂组22例(8.3%),风险比0.76(95%CI 0.41-1.41)。
  • 1年神经功能良好结局(基于脑功能分类评分):干预组14例(5.9%)vs 安慰剂组20例(7.6%),风险比0.78(95%CI 0.41-1.49)。
  • 6个月与1年时,两组神经功能良好结局及健康相关生活质量均无差异。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验的长期结局报告(VAM-IHCA试验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:院内心搏骤停患者给予血管加压素与甲泼尼龙,与安慰剂相比,未改善长期结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: The primary results from the Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest (VAM-IHCA) trial have previously been reported. The objective of the current manuscript is to report long-term outcomes.

METHODS: The VAM-IHCA trial was a multicenter, randomized, double-blind, placebo-controlled trial conducted at ten hospitals in Denmark. Adult patients (age ≥ 18 years) were eligible for the trial if they had an in-hospital cardiac arrest and received at least one dose of epinephrine during resuscitation. The trial drugs consisted of 40 mg methylprednisolone (Solu-Medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of epinephrine. This manuscript report outcomes at 6 months and 1 year including survival, survival with favorable neurological outcome, and health-related quality of life.

RESULTS: 501 patients were included in the analysis. At 1 year, 15 patients (6.3%) in the intervention group and 22 patients (8.3%) in the placebo group were alive corresponding to a risk ratio of 0.76 (95% CI, 0.41-1.41). A favorable neurologic outcome at 1 year, based on the Cerebral Performance Category score, was observed in 14 patients (5.9%) in the intervention group and 20 patients (7.6%) in the placebo group (risk ratio, 0.78 [95% CI, 0.41-1.49]. No differences existed between groups for favorable neurological outcome and health-related quality of life at either 6 months or 1 year.

CONCLUSIONS: Administration of vasopressin and methylprednisolone, compared with placebo, in patients with in-hospital cardiac arrest did not improve long-term outcomes in this trial.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Granfeldt A, Sindberg B, Isbye D, et al. Effect of vasopressin and methylprednisolone vs. placebo on long-term outcomes in patients with in-hospital cardiac arrest a randomized clinical trial. Resuscitation. 2022. PMID: 35490936. doi:10.1016/j.resuscitation.2022.04.017

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。